Study of ExoFlo for the Treatment of Perianal Fistulas
A Phase IB/IIA Study of ExoFlo, an Ex Vivo Culture-expanded Adult Allogeneic Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicle Isolate Product, for the Treatment of Perianal Fistulizing Crohn's Disease
Sponsor: Direct Biologics, LLC
Terminated
Enrollment challenges.
Other terminated trials from Direct Biologics, LLC
More terminations from Direct Biologics, LLC
Listed as NCT05836883, this PHASE1/PHASE2 trial focuses on Crohn's Disease and Perianal Fistula and remains terminated or withdrawn. Sponsored by Direct Biologics, LLC, it has been updated 7 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Mar 2025 — Present [monthly]
Terminated PHASE1/PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 2 earlier versions
-
Oct 2023 — Mar 2024 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2023 — Oct 2023 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Direct Biologics, LLC
For direct contact, visit the study record on ClinicalTrials.gov .